Back
Friday, 26 Nov, 2021
Prof Ooi Eng Eong on Novavax's application for approval to use its protein-based vaccine in S'pore (CNA)
Novavax is seeking approval for use of its COVID-19 jab in Singapore. If interim permission is granted, it will be the first protein-based coronavirus shot available locally under the Special Access Route. The jab has shown promising results in overseas trials. Prof Ooi Eng Eong from the emerging infectious diseases programme at Duke-NUS Medical School shared his thoughts on protein-based vaccines and how likely they will hold up against coronavirus variants.
Original article: Prof Ooi Eng Eong on Novavax's application for approval to use its protein-based vaccine in S'pore (CNA)